Background: Liver organoids show promise for development as a tissue replacement therapy
Introduction
Organoids are three-dimensional (3D) aggregates of organ-specific cells that selforganize in vitro into in vivo-like tissue structures. Recent advances have led to the generation of retinal, brain, kidney, gut, and liver organoids that recapitulate some of the specific functions of those organs. Importantly, organoids have great therapeutic potential if effective implantation strategies can be developed for organoids to replace diseased or dysfunctional organs in humans. 1 Liver transplantation is currently the only treatment for end-stage liver disease, which is the 12 th leading cause of death by disease in the United States. 2 Transplantation is limited by the severe shortage of donor organs and there is a critical need to develop alternative approaches to replace lost liver function. Human liver organoids have been developed from induced pluripotent stem cells 3 and adult bipotential liver stem cells 4 by culturing in extracellular matrix (ECM) produced by Engelbreth-Holm-Swarm mouse sarcoma cells (marketed under the tradename Matrigel). While initial efforts to implant liver organoids into mouse models showed promising results, they remain limited in that either engraftment sites were ectopic (e.g. brain, kidney capsule, or mesentery) 3 or engraftment efficiency into the liver was low. 4 In addition, engraftment required genetically engineered mouse models 3, 5 or pre-treatment with toxins 4 that conferred a proliferative advantage to implanted cells over endogenous hepatocytes, conditions that could not be recapitulated easily clinically. Implantation experiments were conducted in severely immunodeficient mice [3] [4] [5] and likely do not reflect the immunological reaction that would be elicited in a clinical scenario in humans. Finally, dependence on Matrigel for organoid formation is problematic because Matrigel is a collection of undefined protein products from a xenogenic source that cannot easily be translated into clinical applications.
Our lab has generated liver organoids in rotating wall vessel (RWV) bioreactors that provide an unencumbered 3D spatial environment for cells to self-aggregate and self-organize. 6, 7 This approach has the advantage of efficiently producing bulk cultures of organoids that initiate cellular self-organization in a 3D environment, as opposed to Matrigel-based methods that coax development of 3D structures from a two-dimensional (2D) surface. Moreover, formation of organoids in RWVs does not rely on Matrigel. RWVs produce solid-body rotation with laminar flow, resulting in an idealized suspension culture with low turbulence, low shear stress, and maximal 3D spatial freedom for cells to self-associate. 8 These unique features promote formation of larger aggregates that have decreased hypoxia near the core compared to stationary methods. 9 Organoids that mimic the in vivo architecture of numerous organs, including lung, intestine, bladder, and liver, have been successfully generated in RWVs. 10 Hepatocytes that selfaggregate within RWVs form tight junctions and bile canaliculi 11 and display differentiated characteristics that make them good models to study hepatitis C host-pathogen interactions.
12
Our lab has shown that compared to 2D culture, hepatic organoids generated in RWVs have significantly greater hepatocyte-specific functions and gene expression because of maintained expression of a key master transcriptional regulator, hepatocyte nuclear factor 4 alpha. 6, 7 In this study, we aimed to develop a surgical technique to orthotopically implant hepatic organoids generated within RWVs into the livers of recipient mice. Achieving orthotopic implantation is important because full expression of critical hepatic functions, including bile excretion and processing of portal circulation metabolites, requires engraftment in the unique anatomical location of the liver. We hypothesized that hepatocyte organoids generated in RWVs would produce their own ECM and that the ECM scaffold would be further enhanced by coculture with stellate cells. We used immunocompetent mice as recipients to determine if our surgical approach stimulated immune responses that limited the durability of engraftment.
Finally, novel surgical approaches, including associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), indicate that hepatectomy may be used therapeutically to induce rapid hypertrophy of the remnant liver. 13 Therefore, we tested the effect of performing partial hepatectomy on the recipient liver at the time of organoid implantation as a clinically translatable surgical adjunct to promote organoid engraftment.
Methods
Mice. B6.129S7-Gt(ROSA)26Sor/J (ROSA26) mice (6-12 weeks old), in which -galactosidase was constitutively expressed in all cells, were maintained as a colony in-house. Male or female ROSA26 mice were used as sources of donor hepatocytes and stellate cells. Male wild-type littermates or wild-type C57BL/6 mice purchased from Jackson Laboratory (Bar Harbor, ME)
were used as recipient mice in implantation experiments. All mice were cared for in accordance to the National Institutes of Health "Guide for the Care and Use of Laboratory Animals."
Generation of Liver Organoids. Primary hepatocytes were isolated by two-step perfusion using
Liver Perfusion Medium and Liver Digest Medium (Thermo Scientific, Fremont, CA), and then separated with 50% Percoll (GE Healthcare Life Sciences, Pittsburgh, PA) density gradient.
Primary stellate cells were isolated by three-step perfusion using Liver Perfusion Medium (Thermo Scientific), 0.29% pronase (Roche, Basel, Switzerland), and 0.024% collagenase (Crescent Chemical, Islandia, NY), followed by further digestion in 0.044% pronase and 0.008% Bright-field photos were taken with a Canon EOS Rebel T3i (Canon, Tokyo, Japan) adapted to the photoport of a Nikon Eclipse TS100 microscope (Nikon, Tokyo, Japan).
Orthotopic Liver Organoid Implantation. Liver organoids were collected from RWVs, counted, and resuspended in phosphate buffered saline. PE50 tubing (BD Biosciences, San Jose, CA) was loaded with 1,000 organoids (approximately 1x10 6 cells) and adapted to a glass syringe with screw drive (Hamilton, Reno, NV). For direct orthotopic implantation, a hepatotomy was made in the left liver lobe of recipient mice using a 16-gauge needle, and the organoids were then implanted within the hepatotomy site. For comparison, 1x10 6 freshly isolated single-cell hepatocytes were loaded into PE50 tubing and implanted into the left lobe in the same manner.
In some recipient mice, concurrent two-thirds hepatectomy was carried out by ligating and resecting the median and left lobes, followed by a hepatotomy and organoid implantation in the remaining right liver lobe. Single-cell hepatocytes were injected into the spleen using a 30- AlexaFluor-488 phalloidin (Thermo Scientific) and nuclei were counterstained with 1μg/ml 4'6-diamidino-2-phenylindole (DAPI). In some experiments, stellate cells were pretreated with
CellTracker Red CMTPX dye (Thermo Scientific) prior to culture. Samples were imaged using a Yokagawa CSU22 spinning disk confocal microscope at the UCSF Nikon Imaging Center (San Francisco, CA).
Quantification of Organoid ECM. Using Image J software, we analyzed confocal images of organoids by converting positive staining for each matrix component into binary mode through the histogram threshold function, followed by particle analysis. To calculate the percentage area positive for a specific matrix component, the area positive for that matrix obtained from particle analysis was divided by the cross-sectional area of the entire organoid, which was determined by the tracing tool. This analysis was performed for at least 10 organoids for each matrix component for each condition.
Terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL). TUNEL staining was performed on liver cryosections using the ApopTag Peroxidase In Situ Apoptosis
Detection Kit (Millipore, Billerica, MA) per manufacturer's instructions. Viable nuclei were detected by counterstaining with methyl green (Sigma).
Statistical Analysis. Statistical analyses were performed with Prism v. 5.0 (GraphPad, La Jolla, CA) using either Student's two-tailed t-test or two-way ANOVA. P values < 0.05 were considered statistically significant.
Results

Direct orthotopic implantation of hepatocyte organoids results in local engraftment of
organoids into the implanted liver lobe. To evaluate the engraftment potential of liver organoids generated in RWVs, we isolated primary hepatocytes from ROSA26 C57BL/6 mice, whose cells express β-galactosidase under a ubiquitous promoter and stain blue in the presence of Xgal. Hepatocytes self-organized into organoids 100-200m in size within 3 days of culture in RWVs. 7 Conventional clinical and experimental hepatocyte transplantation entails injecting hepatocytes into the portal circulation through the portal vein or via the spleen. We found that injection of donor Xgal + hepatocytes into recipient spleens resulted in low-efficiency engraftment near portal veins of portal triads within the liver parenchyma ( Figure 1A) , a result consistent with published reports. 14 Rare Xgal + hepatocytes were detected in the spleen up to 3 days after injection, indicating that some donor hepatocytes were retained in the spleen. When we infused hepatic organoids into the spleen, we saw no engraftment of organoids in the liver after 3 days. Clusters of organoids were trapped within the spleen after splenic injection ( Figure   1A ), indicating that organoids were not able leave the spleen, likely due to their larger size and cohesive multicellular structure. We attempted to inject the organoids through the portal vein, however, this was too technically challenging due to the small size of the mouse portal vein.
Because organoids could not be transplanted into the liver via splenic injection, we developed a surgical technique to directly implant the organoids into the liver orthotopically.
First, a hepatotomy was performed using a 16-gauge needle in the recipient liver parenchyma.
Liver organoids were then infused into the hepatotomy site in a slow and controlled manner, using PE50 tubing adapted to a screw-drive glass syringe in a technique modified from murine pancreatic islet transplantation. 15 Using this surgical approach, we achieved consistently high implantation rates of liver organoids as determined by the presence of Xgal + cells in recipient livers after 3 days ( Figure 1B) . As a comparison, we implanted freshly isolated single-cell hepatocytes into the liver parenchyma using the same technique. Single cells appeared to be loosely dispersed within the hepatotomy site, whereas organoids retained their aggregated spheroid architecture and were more compacted within the space ( Figure 1B) . The numbers of Xgal + donor hepatocytes delivered by direct parenchymal implantation were comparable whether hepatocytes were implanted as single cells or as organoids ( Figure 1C) . These results indicate that although organoids could not be transplanted into the liver via splenic injection, they could be implanted into the liver by direct parenchymal implantation. Orthotopic organoid implantation achieves implantation rates comparable to those of single-cell hepatocytes implanted by the same technique.
Hepatocyte-stellate cell organoids demonstrate greater ECM production compared to hepatocyte-alone organoids. Because hepatic stellate cells are the main producers of ECM in the liver, 16 we hypothesized that co-culturing hepatocytes with stellate cells would generate organoids with optimized ECM scaffolds, potentially leading to improved engraftment in host tissue. To generate hepatocyte-stellate cell organoids, we isolated primary hepatocytes and stellate cells from ROSA26 C57BL/6 mice and co-cultured them within RWVs for 3 days at a 10:1 ratio, the normal hepatocyte to stellate cell ratio within the liver. Isolated stellate cells were treated with CellTracker Red CMTPX dye so that they could be identified within hepatocytestellate cell organoids. Confocal microscopy demonstrated that hepatocytes had cortical organization of F-actin and that stellate cell distribution was widespread and uniform among hepatocytes in co-aggregated organoids generated within RWVs (Figure 2A) . Within coaggregated organoids, we detected quiescent stellate cells, which stain positively for desmin and exhibit a round cell shape, as well as activated stellate cells, which stain positively for alpha smooth muscle actin (SMA) and exhibit an elongated cell shape ( Figure 2B ).
To determine whether hepatocyte-stellate cell organoids produced more ECM compared to hepatocyte-alone organoids, we stained both organoid types for the four major ECM components found in normal liver: collagen I, collagen IV, laminin, and fibronectin. Positive staining for each ECM component was determined by confocal microscopy and quantitatively evaluated by digital imaging analysis. In hepatocyte-stellate cell organoids, distribution of collagen I, collagen IV, and laminin increased significantly compared to hepatocyte-alone organoids, whereas fibronectin levels were similar between the two organoid types ( Figure 3A and 3B). These results are consistent with the roles of stellate cells producing collagen I, collagen IV, and laminin and hepatocytes producing mostly fibronectin within the normal liver, 16 and suggest that hepatocyte-stellate cell organoids demonstrate a more complete ECM scaffold than do hepatocyte-alone organoids.
Hepatocyte-stellate cell organoids show engraftment comparable to that of hepatocytealone organoids, whereas partial hepatectomy of the host liver significantly decreases organoid engraftment. To determine whether the improved ECM scaffold of hepatocytestellate cell organoids led to improved engraftment, we implanted ROSA26 C57BL/6
hepatocyte-stellate cell and hepatocyte-alone organoids into the liver parenchyma of wild-type C57BL/6 mice. Recipient livers were collected 3 days later and stained with Xgal to identify implanted organoids. There were no qualitative differences between implantation of the two types of organoids because neither condition demonstrated integration of donor cells with the surrounding host parenchyma ( Figure 4A ). In addition, there were no quantitatively significant differences between the numbers of Xgal + cells detected after hepatocyte-alone versus hepatocyte-stellate cell organoid implantation ( Figure 4B) . These results indicate that the presence of stellate cells in co-aggregrated organoids results in greater ECM production, but does not significantly increase engraftment efficiency.
Since partial hepatectomy stimulated liver regeneration, we hypothesized that performing a two-thirds partial hepatectomy at the time of implantation would induce host liver tissue remodeling and improve organoid integration with the host liver. We implanted hepatocytealone or hepatocyte-stellate cell organoids into recipient mice that either did or did not undergo To temporally correlate organoid viability with the elicited inflammatory response, we first confirmed the viability of the organoids prior to transplantation by trypan blue exclusion.
The vast majority of cells within organoids were viable and excluded trypan blue ( Figure 6A ).
In contrast, hepatocytes that remained as single cells within the RWVs were all dead and trypan blue positive, indicating that cell-to-cell contact and cellular aggregation were critical to maintaining the viability of hepatocytes in rotational suspension culture. We implanted viable hepatocyte organoids orthotopically into the liver of recipient mice and performed terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) staining to detect apoptotic cells at 1 hour and 3 days after implantation. We found that along with many viable appearing hepatocyte nuclei, a substantial number of donor hepatocytes within organoids were already TUNEL + as early as 1 hour after implantation ( Figure 6B) . By day 3, there were no viable hepatocyte nuclei within organoids. Although some hepatocytes demonstrated TUNEL + nuclei, most were anucleated with washed-out cytoplasm, consistent with coagulative necrosis.
These results indicated that while implanted organoids continued to express Xgal at 3 days after implantation, their viability was severely compromised. In order to determine whether the site of implantation influenced the onset the organoid necrosis, we performed TUNEL staining on organoids implanted into the spleen. Similar to the liver, organoids implanted into the spleen displayed a mix of healthy and apoptotic nuclei at 1 hour and all organoids were necrotic by 3 days (Figure 6B) . Freshly isolated single-cell hepatocytes implanted into the liver by the same technique showed more viable cells at 1 hour compared to organoid implantation. However, by day 3, single-cell hepatocytes within the main implantation cavity were also necrotic ( Figure   6B ). These results suggest that organoids are more susceptible to early cell death after parenchymal implantation compared single-cells, but by 3 days, both organoids and single-cells, regardless of site of implantation, succumb to necrosis.
Discussion
The technology for producing highly functional liver organoids is developing rapidly, but effective techniques for engrafting them in vivo for therapeutic organ function replacement is lacking. Conventional single-cell hepatocyte transplantation through the portal circulation has been shown in human clinical trials to have poor engraftment efficiency, durability, and outcomes. 14 The reasons for this include clearance by the immune system and entrapment within hepatic sinusoids. We developed a novel surgical method for introducing liver organoids orthotopically into recipient liver parenchyma by performing a hepatotomy and then implanting organoids directly. We showed that attempts to introduce hepatic organoids into the portal circulation by injecting them into the spleen resulted in the organoids being trapped within the spleen, likely because they are larger than single cells and have a cohesive multicellular structure. Our surgical approach of orthotopic liver organoid implantation is conceptually innovative in that we bypass the requirement for cells to extravasate across portal sinusoids to reach and engraft within the liver.
We demonstrated that hepatocyte organoids generated in RWVs by self-organization produced their own endogenous ECM, and additional ECM was produced in organoids formed by co-culture with stellate cells. Organoid ECM composition recapitulated the in vivo characteristics of hepatocytes, producing mostly fibronectin, and of stellate cells, producing collagen I, collagen IV, and laminin. 16 Quiescent stellate cells play a key role in maintaining ECM homeostasis in the normal liver, 16 and our findings suggest that their presence within liver organoids may be important in maintaining a normal ECM scaffold. Stellate cell activation is required for repairing liver injury and inducing liver regeneration, 17 but continued pathological activation of stellate cells leads to fibrosis and liver dysfunction. 18 Hepatocytes and stellate cells are closely positioned in the Space of Disse in vivo and they cross-regulate each other through paracrine signals. 19 Insulin-like growth factor 1 produced by injured hepatocytes stimulates proliferation of stellate cells, 20 whereas hepatocyte growth factor produced by stellate cells stimulates hepatocyte proliferation and is the key mitogen in liver regeneration. 21 Co-culture experiments have demonstrated that both quiescent and activated stellate cells improve and prolong hepatocyte function in vitro compared to hepatocyte monoculture. [22] [23] [24] [25] We found that both quiescent and activated stellate cells were present in hepatocyte-stellate cell organoids generated in RWVs. Although total ECM content and the diversity of ECM components were increased in hepatocyte-stellate organoids compared to hepatocyte-alone organoids, this difference did not lead to significant improvements in organoid engraftment, suggesting that the composition of organoid ECM scaffolds was not a key determinant of successful engraftment.
Studies to date have investigated liver organoid engraftment in experimental models in which host hepatocytes were manipulated to give transplanted cells a growth advantage. These experimental systems utilized genetically engineered mouse models, such as fumarylacetoacetate hydrolase deficient mice 5 or albumin thymidine kinase transgenic mice, 3 in which specific forms of host hepatocyte injury were induced to facilitate endogenous hepatocyte replacement by exogenously introduced hepatocytes. These studies demonstrated the functional capacity of engrafted liver organoids in vivo, but the experimental conditions favorable for engraftment had limited or no human correlate for clinical translation. Another study used carbon tetrachloride and retrorsine to pre-condition the host livers of mice for organoid engraftment, 4 but the safety and efficacy of those toxins in humans were unknown. Recent advances in surgery indicate that hepatectomy may be used therapeutically to induce hypertrophy in the remnant liver and permit extensive resection of liver tumors. 13 We hypothesized that hepatectomy may be used to induce improved engraftment and/or proliferation of orthotopically implanted liver organoids. We hepatocyte transplantation through the portal vein produces less acute inflammation, but engraftment efficiency is low due to entrapment of donor cells within sinusoids and clearance by the reticulo-endothelial system. 14 Efficient transplantation of organoids through the portal system may be even more challenging due to their larger size and multi-cellular structure.
Additional innovation is required to facilitate engraftment of exogenous hepatocytes or organoids into the liver and need to address the inflammatory/immunological response.
Our analysis showed that at 1 hour after implantation, there was neutrophilic infiltration around the organoids, consistent with a response to acute tissue injury. At this same time point, a substantial number of donor hepatocytes within organoids had TUNEL + nuclei, indicating that they were undergoing apoptosis. Our surgical technique of direct parenchymal implantation produced traumatic tissue injury to the host liver that likely stimulated a neutrophil response. In addition, another source of tissue injury at the implantation site might have been ischemiareperfusion injury of the organoids. Ischemia-reperfusion injury is an important cause of organ dysfunction after major liver resections and liver transplantation. 26 Liver organoids may have experienced ischemia-reperfusion as a consequence of transfer from the bioreactor followed by subsequent reperfusion by blood released from disrupted sinusoids at the implantation site. Our data showed that viability of single-cells was better than organoids at 1 hour after implantation, suggesting that organoids may be more vulnerable to ischemia. Parenchymal cells in the liver and intestine undergo apoptosis 1 hour after reperfusion in experimental transplantation models, 27, 28 a time course similar to the onset of hepatocyte apoptosis in implanted organoids.
Eventually, the dominant mode of cell death after ischemia-reperfusion injury was necrosis, 28 also similar to what we observed after organoid implantation. Ischemia-reperfusion injury is characterized by induction of oxidative stress, parenchymal cell apoptosis, and immune activation. 26 Our findings suggest that for orthotopic liver organoid implantation to succeed clinically, the acute inflammatory response induced by tissue injury from the implantation procedure, and potentially from ischemia-reperfusion, must be minimized. Various approaches aimed at reducing the inflammatory consequences of tissue injury are currently under investigation, including pre-operative conditioning, administration of anti-oxidants, nitric oxide agonists, anti-apoptotic and anti-inflammatory agents. 29, 30 Novel immunomodulatory agents that inhibit natural IgM antibodies and complement activation have also been shown to dampen the acute inflammation caused by tissue injury. 31, 32 Our data suggest that these novel approaches to reduce acute inflammation will likely be important adjuncts to improve the efficiency and durability of orthotopic liver organoid implantation.
In conclusion, liver organoids generated in RWVs produced endogenous ECM scaffolds and could be further developed for in vivo tissue replacement therapy for patients with end-stage liver disease. Further optimization of clinically modifiable organoid and host factors are needed to improve the durability of orthotopic liver organoid engraftment. 
